A detailed history of New Edge Advisors, LLC transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 34 shares of KRYS stock, worth $6,055. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34
Previous 34 -0.0%
Holding current value
$6,055
Previous $6,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$108.51 - $130.22 $28,104 - $33,726
-259 Reduced 88.4%
34 $3,000
Q1 2023

May 12, 2023

SELL
$72.39 - $84.27 $441,144 - $513,541
-6,094 Reduced 95.41%
293 $23,000
Q4 2022

Feb 14, 2023

BUY
$63.14 - $79.9 $1,831 - $2,317
29 Added 0.46%
6,387 $505,000
Q3 2022

Nov 14, 2022

BUY
$64.85 - $82.4 $412,316 - $523,899
6,358 New
6,358 $443,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $4.57B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.